Increasing Survival in Stage III NSCLC: Optimizing Care and Addressing New Clinical Challenges

Join us for this live, CME/MOC-certified symposium featuring review and discussion of patient case studies and key clinical trial data by renowned clinical experts. The symposium will cover recent advances in the use of immunotherapy to optimize outcomes in patients with stage III NSCLC.

You will have multiple opportunities to interact with faculty through interactive patient case scenarios and dynamic question and answer sessions.

Increasing Survival in Stage III NSCLC: Optimizing Care and Addressing New Clinical Challenges, content and views expressed therein are those of the Clinical Care Options, LLC and not of SITC.

Agenda

Welcome and Introduction  

Stage III NSCLC: Background

Case Discussions on Optimal Integration of Checkpoint Inhibitors into the Management of Stage III NSCLC

Future Directions: Immune Checkpoint Inhibitors In Early Stage NSCLC

Final Thoughts: Panel Discussion and Audience Question and Answer Session

Faculty

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of oncology specialists and other clinicians to integrate immune checkpoint inhibitors into treatment of their patients with stage III non-small-cell lung cancer.

Target Audience 
This program is intended for physicians and other healthcare providers who care for patients with non-small-cell lung cancer.

Learning Objectives

  • Discuss the biologic rationale for using immune checkpoint inhibitors in patients with locally advanced NSCLC
  • Plan optimal, individualized therapeutic strategies for patients with stage III NSCLC, considering the available clinical evidence, expert recommendations, and patient preferences
  • Identify subsets of patients with stage III NSCLC most likely to benefit from durvalumab consolidation after definitive platinum-based chemotherapy and concurrent radiation therapy
  • Identify subsets of patients with stage III NSCLC most likely to benefit from pembrolizumab
  • Describe ways that the use of immunotherapy in earlier stages of disease may require a different understanding of risk/benefit and applicable subsets of patients
  • Manage immune-mediated adverse events with the use of automated decision support resources and guidelines

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE MAINTENANCE OF CERTIFICATION
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

If you are interested in having us report ABIM MOC, please ensure the following information is provided within your Member Profile:

Name - as registered with ABIM
Date of Birth (Month/Day)
Your ABIM ID number

Learners must complete the post-test with a passing score of 70% and provide additional documentation following the symposium.  

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.